The AMA Council on Drugs has reviewed a preliminary report of the University Group Diabetes Program (UGDP) study of phenformin as treatment of asymptomatic diabetes. The report appears elsewhere in this issue of The Journal (p 777).
The Council concludes that the UGDP has produced no data indicating that therapy directed toward lowering the blood glucose level in adult-onset, asymptomatic diabetic patients decreases mortality or lowers the incidence of nonfatal cardiovascular complications.
Moreover, the findings of this study suggest that over a long period of time phenformin treatment and diet may be less effective than diet alone or diet plus insulin insofar as cardiovascular death rate is concerned.
John C. Ballin. Phenformin Treatment of Diabetes. JAMA. 1971;217(6):817. doi:10.1001/jama.1971.03190060055013